{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:42:50Z","timestamp":1725705770021},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/mou.0b013e328356adff","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T12:00:33Z","timestamp":1343476833000},"page":"405-414","source":"Crossref","is-referenced-by-count":8,"title":["Strategies to prevent progression of high-risk bladder cancer at initial diagnosis"],"prefix":"10.1097","volume":"22","author":[{"given":"Ja H.","family":"Ku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210206","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R2-11-20210206","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2004.03.017","article-title":"Noninvasive urothelial neoplasms: according to the most recent WHO classification.","volume":"46","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"R3-11-20210206","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in nonmuscle-invasive bladder cancer: from epidemiology to treatment strategy.","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"R4-11-20210206","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.juro.2009.08.083","article-title":"Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.","volume":"182","author":"Cho","year":"2009","journal-title":"J Urol"},{"key":"R5-11-20210206","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1464-410X.2008.08011.x","article-title":"The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.","volume":"103","author":"Streeper","year":"2009","journal-title":"BJU Int"},{"key":"R6-11-20210206","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.urology.2007.06.638","article-title":"Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.","volume":"70","author":"Andius","year":"2007","journal-title":"Urology"},{"key":"R7-11-20210206","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethraareprognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin.","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"R8-11-20210206","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: precystectomy prostate involvement as a prognostic factor.","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"R9-11-20210206","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","article-title":"The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.","volume":"175","author":"Kamat","year":"2006","journal-title":"J Urol"},{"key":"R10-11-20210206","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cncr.22756","article-title":"Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.","volume":"110","author":"Kamat","year":"2007","journal-title":"Cancer"},{"key":"R11-11-20210206","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.urology.2010.11.043","article-title":"Neoadjuvant systemic therapy or early cystectomy Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder.","volume":"77","author":"Ghoneim","year":"2011","journal-title":"Urology"},{"key":"R12-11-20210206","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.juro.2010.02.026","article-title":"The role of tumor-free status in repeat resection before intravesical bacillusCalmette-Guerin for high grade Ta, T1 and CIS bladder cancer.","volume":"183","author":"Guevara","year":"2010","journal-title":"J Urol"},{"key":"R14-11-20210206","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","article-title":"Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.","volume":"29","author":"Stadler","year":"2011","journal-title":"J Clin Oncol"},{"key":"R15-11-20210206","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0090-4295(00)00756-1","article-title":"Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.","volume":"56","author":"Shariat","year":"2000","journal-title":"Urology"},{"key":"R16-11-20210206","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"R17-11-20210206","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","article-title":"Pathological stage review is indicated in primary pT1 bladder cancer.","volume":"106","author":"vanRhijn BW, van der Kwast","year":"2010","journal-title":"BJU Int"},{"key":"R18-11-20210206","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder, the 2011 update.","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"R19-11-20210206","first-page":"728","article-title":"Should urologists be spending more time on the golf course BJU I","volume":"100","author":"Ray","year":"2007","journal-title":"nt"},{"key":"R20-11-20210206","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.eururo.2009.07.005","article-title":"Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"R21-11-20210206","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1089\/end.2011.0081","article-title":"Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis.","volume":"25","author":"Vianello","year":"2011","journal-title":"J Endourol"},{"key":"R22-11-20210206","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial.","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"key":"R23-11-20210206","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"R24-11-20210206","first-page":"504","article-title":"How to improve the effectiveness of transurethral resection in nonmuscle invasive bladder cancer Curr Opin U","volume":"19","author":"Cauberg","year":"2009","journal-title":"rol"},{"key":"R25-11-20210206","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.urology.2008.02.002","article-title":"Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer.","volume":"72","author":"Goh","year":"2008","journal-title":"Urology"},{"key":"R26-11-20210206","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jbio.200710017","article-title":"Endoscopic OCT with forward-looking probe: clinical studies in urology and gastroenterology.","volume":"1","author":"Zagaynova","year":"2008","journal-title":"J Biophotonics"},{"key":"R27-11-20210206","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1111\/j.1464-410X.2011.10090.x","article-title":"Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in TaT1 patients: a randomized two-centre study.","volume":"108","author":"Hermann","year":"2011","journal-title":"BJU Int"},{"key":"R28-11-20210206","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eururo.2009.10.030","article-title":"Transurethral resection of nonmuscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.","volume":"57","author":"Schumacher","year":"2010","journal-title":"Eur Urol"},{"key":"R29-11-20210206","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.25523","article-title":"Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial.","volume":"117","author":"Stenzl","year":"2011","journal-title":"Cancer"},{"key":"R30-11-20210206","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"key":"R32-11-20210206","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1464-410X.2007.07317.x","article-title":"Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder.","volume":"101","author":"Bryan","year":"2008","journal-title":"BJU Int"},{"key":"R33-11-20210206","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1464-410X.2008.07846.x","article-title":"A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences.","volume":"102","author":"Herr","year":"2008","journal-title":"BJU Int"},{"key":"R34-11-20210206","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00345-011-0659-2","article-title":"Narrow band imaging-assisted transurethral resection for nonmuscle invasive bladder cancer significantly reduces residual tumour rate.","volume":"29","author":"Cauberg","year":"2011","journal-title":"World J Urol"},{"key":"R35-11-20210206","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.eururo.2012.01.018","article-title":"A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on nonmuscle-invasive bladder cancer recurrence.","volume":"61","author":"Naselli","year":"2012","journal-title":"Eur Urol"},{"key":"R36-11-20210206","first-page":"146","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach Eur U","volume":"53","author":"Denzinger","year":"2008","journal-title":"rol"},{"key":"R38-11-20210206","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"; Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guerin with or without interferon -2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"R39-11-20210206","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"R40-11-20210206","first-page":"710","article-title":"Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough C","volume":"113","author":"Decobert","year":"2008","journal-title":"ancer"},{"key":"R41-11-20210206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for nonmuscle-invasive bladder cancer.","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"key":"R42-11-20210206","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.","volume":"17","author":"Koga","year":"2010","journal-title":"Int J Urol"},{"key":"R43-11-20210206","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Guerin without maintenance therapy for high-risk nonmuscle-invasive bladder cancer.","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"R44-11-20210206","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1016\/S1569-9056(12)61046-X","article-title":"Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer.","volume":"11","author":"Brausi","year":"2012","journal-title":"Eur Urol Suppl"},{"key":"R45-11-20210206","first-page":"971","article-title":"Is maintenance Bacillus Calmette-Guerin really necessary Eur U","volume":"54","author":"Herr","year":"2008","journal-title":"rol"},{"key":"R46-11-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for nonmuscle-invasive bladder cancer.","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"R47-11-20210206","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of bacillus Calmette-Guerin in the treatment of nonmuscle-invasive bladder cancer.","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol"},{"key":"R48-11-20210206","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","article-title":"Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomisedFinnBladder I study with a 20-year follow-up.","volume":"56","author":"Jarvinen","year":"2009","journal-title":"Eur Urol"},{"key":"R49-11-20210206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study.","volume":"84","author":"Porena","year":"2010","journal-title":"Urol Int"},{"key":"R50-11-20210206","first-page":"25","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.","volume":"57","author":"Duchek","year":"2010","journal-title":"EurUrol"},{"key":"R51-11-20210206","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"R52-11-20210206","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1002\/cncr.24634","article-title":"Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.","volume":"115","author":"Kulkarni","year":"2009","journal-title":"Cancer"},{"key":"R53-11-20210206","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacilleCalmette-Guerin failure pattern on subsequent response to bacilleCalmette-Guerin plus interferon intravesical therapy.","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"R54-11-20210206","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed.","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"key":"R55-11-20210206","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"R56-11-20210206","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","article-title":"A single-institution experience with induction and maintenance intravesical docetaxel in the management of nonmuscle-invasive bladder cancer refractory to bacilleCalmette-Guerin therapy.","volume":"104","author":"Barlow","year":"2009","journal-title":"BJU Int"},{"key":"R57-11-20210206","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol Oncol"},{"key":"R58-11-20210206","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacilleCalmette-Guerin after initial bacilleCalmette-Guerin failure in nonmuscle-invasive bladder cancer: a multicenter prospective randomized trial.","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"4S","key":"R59-11-20210206","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1016\/j.juro.2012.02.1524","article-title":"SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Non-Muscle Invasive Bladder Cancer Who Recurred Following at Least Two Prior Courses of BCG.","volume":"187","author":"Skinner","year":"2012","journal-title":"J Urol"},{"key":"R60-11-20210206","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"R61-11-20210206","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"R62-11-20210206","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with nonmuscle invasive bladder cancer.","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"R63-11-20210206","first-page":"2318","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy J Clin O","volume":"24","author":"Weiss","year":"2006","journal-title":"ncol"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0b013e328356adff","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:09:09Z","timestamp":1620965349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201209000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e328356adff","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}